Mark Uhlik, Ph.D., is a seasoned leader in translational oncology and drug discovery/development with over 15 years of experience in the pharmaceutical industry. Prior to Hibercell, Mark served as senior vice president of translational oncology at Biothera Pharmaceuticals Inc., where he led multiple efforts to support the development of their lead asset. Before joining Biothera, Mark was an investigator in the Oncology Division at Eli Lilly and Company. Mark has authored over 35 peer-reviewed publications in addition to book chapters and patents.
Mark earned his B.S. in microbiology from Colorado State University. While at the Pennsylvania State University College of Medicine, Mark received his Ph.D studying the NF-kB signaling pathway and its role in T-cell activation and HTLV-I-mediated pathogenesis. He continued on to postdoctoral work within the lab of Dr. Gary Johnson, first at University of Colorado Health Sciences Center in Denver and then at University of North Carolina School of Medicine.